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Abstract
Recent studies have shown that a tumor-supportive microenvironment is characterized by high levels of pro-inflammatory
and pro-angiogenic eicosanoids derived from omega-6 (n26) arachidonic acid (AA). Although the metabolic pathways
(COX, LOX, and P450) that generate these n26 AA eicosanoids have been targeted, the role of endogenous AA production
in tumorigenesis remains unexplored. Delta-6 desaturase (D6D) is the rate-limiting enzyme responsible for the synthesis of
n26 AA and increased D6D activity can lead to enhanced n26 AA production. Here, we show that D6D activity is
upregulated during melanoma and lung tumor growth and that suppressing D6D activity, either by RNAi knockdown or a
specific D6D inhibitor, dramatically reduces tumor growth. Accordingly, the content of AA and AA-derived tumor-
promoting metabolites is significantly decreased. Angiogenesis and inflammatory status are also reduced. These results
identify D6D as a key factor for tumor growth and as a potential target for cancer therapy and prevention.
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Introduction
The identification of factors that modulate tumorigenesis is
crucial for cancer prevention and treatment. Most studies on
cancer drug discovery have tried to target cell proliferation using
cell- based screening systems to identify anti-cancer compounds;
however, the translation of such discoveries into cancer therapy
has had limited success [1,2]. Current research shows that
targeting cancer metabolism or factors that modulate the tumor
microenvironment may be promising venues for cancer therapy
[3,4].
Arachidonic acid (AA), an omega-6 (n26) polyunsaturated fatty
acid, is converted through three major pathways– the cyclooxy-
genase (COX), lipoxygenase (LOX), and cytochrome P450
epoxygenase pathways–into bioactive lipid mediator eicosanoids,
including prostaglandins (PGs), leukotrienes (LTs), and epoxyei-
cosatrienoids (EETs), respectively [5,6] (Figure S1). These
metabolites have crucial roles in chronic inflammation and cancer
[5–7]. Increased AA metabolism and eicosanoid formation is a
common feature of various types of cancer cells [8,9]. AA-derived
pro-inflammatory eicosanoids, particularly PGE2 and LTB4 which
are produced by tumor cells and their surrounding stromal cells,
are key mediators in their crosstalk and can accelerate tumor
growth and metastasis through several mechanisms [5], including:
1) directly activating their receptors on tumor cells to induce cell
proliferation, survival, migration, and invasion through multiple
signaling pathways in both autocrine and paracrine manners, 2)
directly inducing cancer cells to secrete growth factors, pro-
inflammatory mediators and angiogenic factors that turn a normal
microenvironment into one that supports tumor growth and
spread, and 3) directly binding receptors on stromal cells to
promote a tumor-supportive microenvironment by inducing
angiogenesis and evading attack by the immune system [5].
Certain hydroxyeicosatetraenoic acids (HETEs) and EETs derived
from AA through the LOX and cytochrome P450 epoxygenase
pathways have also been shown to promote angiogenesis, tumor
growth and metastasis [10,11]. Evidently, AA metabolites play a
significant role in tumorigenesis, mainly through the promotion of
inflammation and angiogenesis.
Given the importance of AA metabolites in cancer biology,
many studies have developed anti-cancer drugs targeting the
major pathways (COX, LOX, or P450) of AA metabolism [5].
Although some of the drugs targeting eicosanoid signaling, such as
aspirin and celecoxib, have shown efficacy in suppressing cancer,
they have also been associated with unacceptable toxicity [5,12];
thus, other strategies must be identified for targeting AA
metabolism. Regarding tumorigenesis, the role of endogenous
AA production, which occurs upstream of these metabolic
pathways (Figure S1), remains unexplored.
AA, which is highly abundant in the modern Western diet and
in body tissues [13,14], is synthesized from linoleic acid (LA)
through a series of elongation and desaturation enzyme systems.
Among these enzymes, delta-6 desaturase (D6D) is the first and
rate-limiting step in the production of AA (Figure S1). Thus far,
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Here, we show that D6D activity is up-regulated during the
growth of melanoma and lung tumors and that suppressing D6D
activity dramatically reduces tumor growth. Our results suggest
that D6D is a key factor for tumor growth, and therefore, it is a
potential target for cancer therapy and prevention.
Methods
Ethics Statement
All animal procedures were carried out in accordance with the
guidelines set by the Massachusetts General Hospital Animal
Committee and with IACUC approval (Protocol #
2010N000038). All efforts possible were made to limit animal
suffering.
D6D RNAi Lentivirus Vector and Stable Cell Lines
The Bam HI site of the transfer plasmid pHRST-IRES-GFP
was inactivated by blunting the sticky ends with Klenow I and
religating with T4 DNA ligase. Then, the RNAi lentivirus vector
pLu6-RNAi was obtained by inserting two copies of the hU6
promoter into the Eco RI site of the plasmid. The D6D RNAi
lentivirus vector pLu6-RNAi-D6D was obtained by ligating short
hairpin mouse D6D oligonucleotides with the large fragment of
pLu6-RNAi after Bam HI and Xho I digestion and agarose gel
electrophoresis (Figure S2). 293T cells (ATCC: CRL-11268,
Manassas, VA, authenticated prior to accession by DNA
fingerprinting) were transfected with pLu6-RNAi or pLu6-
RNAi-D6D transfer plasmid and pHDM-G, pHDM-tat1b,
pHDM-Hgpm2, and pRC/CMV-rev1B helper plasmids using
SuperFect transfection reagent. Twenty-four and 48 hours after
transfection, the lentivirus-containing supernatant was harvested
and added to B16-F0 (ATCC: CRL-6322, Manassas, VA) and
LLC cells (ATCC: CRL-1642, Manassas, VA) in a media
supplemented with 8 mg/ml polybrene. The GFP-positive cells
of vector control and D6D-RNAi were sorted on FACSAriaII (BD
Biosciences (Billerica, MA) 7 days after virus infection.
Mouse Tumor Models
Female C57BL6 mice were used for this study. Animals were
fed a diet high in n26 and very low in n23 fatty acids (Table S1)
(Mod AIN-76A with safflower oil; Land O’Lakes Purina Feed,
LLC, Richmond, IN) until the desired age (10–12 weeks) for
experiments was reached. Each mouse was injected subcutane-
ously into both sides of the lateral abdomen with 2610
6 B16-F0 or
LLC cells suspended in 50 ml of PBS. To obtain tumor tissues of
different sizes, the mice were sacrificed and the tumor tissues were
harvested at 2- to 4-day intervals. To investigate the antitumor
effects of SC-26196, wild type B16-F0 or LLC cancer cell-bearing
mice were intragastrically injected with SC-26196 (100 mg/kg
body weight/day; the SC-26196 was kindly provided by the
Chemical Synthesis and Drug Supply Program (CSDSP) of the
National Institute of Mental Health (NIMH), Bethesda, MD,
USA) that was suspended in 0.5% methyl cellulose. Tumor
volume, based on caliper measurements, was calculated every day
(B16-F0) or every 2 days (LLC) according to the following formula:
tumor volume=the shortest diameter
26the largest diameter60.5.
After 14 days (B16-F0) or 25 days (LLC) of inoculation, the mice
were sacrificed, and the tumor tissues were harvested and stored at
270uC.
Analysis of Fatty Acids and Eicosanoids
The fatty acid composition of cultured cells and tissues was
analyzed by gas chromatography as previously described [15]. For
the measurement of eicosanoids, a quantity of 50 mg of tumor
tissue was homogenized in 2 ml water on ice for 45 s. Methanol
and water were added to make the total 3 ml 15% methanol. The
homogenate was incubated for 1 h on ice after adding 30 ng D4-
PGE2 and 300 ng D4-LA (internal standards) and vortexing. The
pH was adjusted to 3.0 with 0.2 M HCl. The mixture was loaded
on a SPE column preconditioned with 2 ml methanol and 2 ml
water. The SPE column was washed with 1 ml water, and the
eicosanoids were eluted with 3 ml ethyl acetate. The ethyl acetate
solution was dried under nitrogen. The residue was dissolved in
200 ml methanol, and 50 ml were subjected to LC/MS analysis.
The Agilent 1200 Series Liquid Chromatography/Mass Selective
Detector (LC/MSD) system was used for separation and detection.
A gradient chromatographic separation was performed on a
ZORBAX Eclipse XDB-C18 column (Agilent, 5 mm, 7564.6 mm)
at 25uC. The detection was made in the negative mode. D4-PGE2
was used as an internal standard for quantification of all
eicosanoids. The concentrations of eicosanoids in the samples
were calculated by comparing their ratios of the peak areas of the
compounds to the internal standards (Figure S3).
Angiogenesis Assay
Microvessel density in tumors was determined by immunohis-
tological staining using an anti-CD31 antibody and expressed as a
percentage of CD31 stained area per section, as described
previously [16]. An in vivo angiogenesis assay was performed as
described by Ito et al. [17] with the following modifications.
Geltrex
TM Basement Membrane Matrix 0.4 mL premixed with
bFGF (5 mg/ml) with and without 100 mM SC-26196 was injected
subcutaneously into C57BL6 mice (3 mice/group). Mice were
sacrificed 7 days after injection and dissected to expose the
implants for recording.
Statistical Analysis
Comparisons were made between the 2 treatments using
Student’s t tests. Differences in tumor growth rate between the
control and treatment (D6D-RNAi or D6D inhibitor) groups or
between B16 melanoma and LLC lung cancer groups was
evaluated by two-way repeated measures ANOVA analyses
followed by Bonferroni tests. Linear regression analysis was used
for determining the significance of associations between log-
transformed tumor size and D6D activity or expression. Differ-
ences were considered significant at the level of P,0.05. Statistical
analysis was performed using GraphPad Prism 5 (La Jolla, CA).
Results
D6D Activity is Higher in Tumor Tissue than in Adjacent
Non-tumor Tissue
To determine whether there is a difference in D6D activity
between tumor and non-tumor tissues, we analyzed the activity of
biomarkers of the D6D enzyme and expression levels in tumor and
non-tumor tissues from B16 melanoma and Lewis lung cancer
(LLC) tumors implanted in C57B6 mice. Since D6D catalyzes the
first rate-limiting step of the enzymatic conversion of LA to AA,
with the formation of eicosatrienoic acid (ETA) as an intermediate
product, the ratios of ETA to LA and AA to LA reflect the activity
of the biomarkers of D6D [18]. The results show that the tumor
tissue content of AA was 4 times greater for B16 melanoma
(Figure 1A) and 2 times greater for LLC tumors (Figure 1B),
compared to adjacent non-tumor tissues. Accordingly, the ETA/
LA and AA/LA ratios were significantly higher in both tumor
tissues than in their adjacent non-tumor tissues (Figures 1A, 1B).
To determine whether the higher D6D activity observed was due
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protein levels. As seen in Figure 1, the D6D mRNA expression
levels were 40 times higher in tumor tissues than in adjacent non-
tumor tissues (Figure 1C) whereas D6D protein was abundantly
expressed in tumor tissues but almost undetectable in adjacent
normal tissues (Figure 1D). These data indicate that D6D is up-
regulated in tumor tissue.
We also examined whether there was a correlation between
tumor size and D6D activity. The activity of the biomarkers of
D6D was analyzed in B16 and LLC tumors of different sizes. As
shown in Figure 1E, the ETA/LA and AA/LA ratios were
positively correlated with the sizes of both the B16 and LLC
tumors (ETA/LA in B16 melanoma: P=0.0015, r
2=0.58; AA/
LA in B16 melanoma: P=0.0025, r
2=0.55; ETA/LA in LLC
tumors: P=0.0001, r
2=0.70; AA/LA in LLC tumors: P=0.0017,
r
2=0.54). D6D mRNA expression levels were also correlated with
tumor size in the B16 melanoma (P=0.0017, r
2=0.93) and LLC
tumors (P=0.0139, r
2=0.81) (Figure 1F). These results suggest a
positive correlation between the activity of the biomarkers of D6D
and tumor growth.
Reducing D6D Activity Suppresses Tumor Growth
To examine the role of D6D in tumorigenesis, we reduced D6D
activity either by knocking down D6D expression with RNAi or by
inhibiting D6D enzyme activity with SC-26196, a highly selective
inhibitor of D6D [19]. We then measured the growth rate of the
B16 melanoma and LLC tumors in mice. Our data indicate that
treatment with RNAi or SC-26196 can effectively reduce D6D
activity (Figures S4, S5 and S6).
D6D-RNAi or the D6D selective inhibitor SC-26196 remark-
ably suppressed the growth of the B16 melanoma and LLC tumors
(Figure 2). For the B16 melanoma model, all control groups of
mice developed palpable B16 melanoma tumors by day 7 whereas
the treatment groups (D6D-RNAi or SC-26196) did not develop
palpable tumors until days 10 (Figure 2A) and 12 (Figure 2B),
respectively, over an observation period of 14 days. The tumor
growth rate of B16 melanoma treated with D6D-RNAi or SC-
26196 was much slower than that of the control group
(Figures 2A, 2B). The percent inhibition of B16 melanoma
growth (based on tumor weight after harvest) by D6D-RNAi and
SC-26196 was 53613% (P,0.01) and 9166% (P,0.01), respec-
tively. The mice treated with SC-26196 showed no signs of
significant toxicity, which may include reduced mobility, reduced
body weight, piloerection, hunched-back posture, anorexia,
diarrhea, or somnolence.
Similarly, for the LLC tumor model, all control groups of mice
developed palpable tumors by day 7 whereas the treatment groups
(SC-26196 or D6D-RNAi) developed palpable tumors by days 13
(Figure 2C) and 15 (Figure 2D), respectively, over an
observation period of 25 days. The growth rates of LLC tumors
treated with D6D-RNAi or SC-26196 were both significantly
slower when compared to that of the control groups (Figures 2C,
2D). The percent inhibition of LLC tumor growth (based on
tumor weight after harvest) by D6D-RNAi and SC-26196 were
3266% (P,0.05) and 4265% (P,0.01), respectively. These data
indicate that reduction of D6D activity is highly effective in
suppressing tumor growth, especially for B16 melanoma.
Decreased D6D Reduces the Levels of AA and AA-derived
Eicosanoids in Tumor Tissue
To test whether decreased D6D results in reduced production of
AA and its metabolites in tumor tissue, we measured the levels of
AA and AA-derived eicosanoids in tumor tissues by gas
chromatography (GC) and liquid chromatography-mass spectrom-
etry (LC-MS). As shown in Figure 3A and Table 1, the tumor
content of AA decreased by 47–69% in D6D-RNAi- or SC-26196-
treated B16 melanoma and LLC tumors as compared to the
control groups. The levels of AA-derived eicosanoids (including
PGD2, PGE2, 12-HETE, and 15-HETE) decreased by 80–95% in
D6D-RNAi- or SC-26196-treated B16 melanoma compared to
the control groups (Figure 3B). A significant reduction of AA-
derived eicosanoids was also observed in D6D-RNAi- and SC-
26196-treated LLC tumors; however, the degree of inhibition was
lower compared with that observed in B16 melanoma. These
results are consistent with the inhibitory effects of reduced D6D on
tumor growth in the treated B16 and LLC tumors.
Figure 1. D6D activity is higher in tumor tissue than in adjacent non-tumor tissue. (a) The activity of biomarkers of D6D in B16 melanoma.
Upper: Gas chromatography showing the differences in LA, ETA and AA content between B16 melanoma and adjacent non-tumor tissue. Lower: The
ratios of ETA/LA and AA/LA indicate D6D enzyme activity. **P,0.01, n=4. (b) Activity of biomarkers of D6D in LLC tumors. Upper: Gas
chromatography showing the differences in LA, ETA and AA content between LLC tumor and adjacent non-tumor tissue. Lower: The ratios of ETA/LA
and AA/LA indicate D6D enzyme activity. **P,0.01, n=4. (c) D6D mRNA levels in tumor and adjacent non-tumor tissue. **P,0.01, n=3. (d) Western
blot showing D6D protein levels in tumor and adjacent non-tumor tissue. (e) Correlation of the activity of biomarkers of D6D (based on ETA/LA and
AA/LA ratios) with tumor size. (f) Correlation of D6D mRNA levels with tumor size.
doi:10.1371/journal.pone.0047567.g001
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Inflammation
Because D6D inhibition does not seem to significantly affect cell
proliferation in in vitro models (Figure S7), we suspect that the
anti-tumor effects of D6D inhibition may be due to its influence on
characteristics of the tumor microenvironment, such as angiogen-
esis and inflammation. Therefore, we examined whether de-
creased D6D affects the status of tumor angiogenesis and
inflammation. The effects of D6D inhibition on angiogenesis
status were measured by both a Matrigel plug assay and
immunohistological staining (IHS). As shown in Figure 4A, SC-
26196 at 100 mM significantly inhibited basic fibroblast growth
factor (bFGF)-induced angiogenesis in a Matrigel plug assay by
64% (P,0.01). Furthermore, the angiogenesis evaluated by IHS
was significantly decreased in D6D-RNAi- or SC-26196-treated
B16 melanoma (Figure 4B) and LLC tumors (Figure 4C)
compared to their respective control groups (P,0.01). The
inhibitory effects on angiogenesis in treated B16 melanoma were
stronger than those in treated LLC tumors. The inflammation
status in B16 melanoma and LLC tumors with and without D6D
inhibition was determined by measuring gene expression of the
inflammatory cytokines IL-6 and TNF-alpha. As shown in
Figure 4D, knocking down or inhibiting D6D reduced mRNA
expression of IL-6 and TNF-alpha expression in B16 and LLC
tumors, suggesting a reduced inflammatory state in the treated
tumors. The results support an anti-angiogenic and anti-inflam-
matory effect of D6D inhibition.
Discussion
Tumor initiation and progression require a tumor-supporting
microenvironment, such as inflammation and angiogenesis [4,5].
Metabolites of AA have long been known to be critical pro-
angiogenic and pro-inflammatory mediators [5]. Therefore,
inhibitors of cyclooxygenase such as COX-2 have been a subject
of intense research, and COX-2 has been well recognized as an
Figure 2. Reducing D6D expression or activity suppresses tumor growth. (a) Effect of D6D-RNAi knockdown on B16 melanoma growth.
**P,0.001; n=8 for both groups. (b) Effect of the D6D selective inhibitor SC-26196 on B16 melanoma growth. **P,0.0001; control, n=7; treated,
n=8. (c) Effect of D6D-RNAi knockdown on LLC tumor growth. *P,0.05; n=8 for both groups. (d) Effect of the D6D selective inhibitor SC-26196 on
LLC tumor growth. **P,0.01; control, n=7; treated, n=10. (a–d) Upper left: Representative tumor sizes. Upper right: Average tumor weight at the end
of the experiment. Lower: Tumor growth rate during the 14-day experimental period.
doi:10.1371/journal.pone.0047567.g002
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information on whether the endogenous synthesis of AA affects
eicosanoid production and tumorigenesis. In this study, we show
that D6D, the rate-limiting enzyme for AA synthesis, is up-
regulated in tumor tissues and that suppression of its expression or
activity results in a remarkable reduction of tumor growth
associated with a decrease in AA-derived eicosanoids, angiogen-
esis, and inflammation in tumor tissues. These results demonstrate
that D6D is a potentially critical factor for tumorigenesis and that
targeting this enzyme is effective in suppressing tumor growth.
D6D catalyzes the first and rate-limiting step of the conversion
of essential fatty acids, which is converting n26 linoleic acid (LA,
18:2n26) and n23 a-linolenic acid (ALA, 18:n23) to the longer
chain polyunsaturated fatty acids (LC-PUFA) arachidonic acid
(AA, 20:4n26) and eicosapentaenoic acid (EPA, 20:5n23),
respectively. These two classes of PUFA compete with each other
for the same metabolizing enzymes but their metabolites are
functionally distinct and often have opposing physiological effects
[6,7,20]. For example, the n26 PUFA-derived metabolites
promote inflammation and angiogenesis, whereas those derived
from n23 PUFA have anti-inflammatory and anti-angiogenic
properties [7,21,22]. Although D6D prefers ALA as a substrate
[23], LA (the n26 substrate of D6D) is much more abundant in
the modern Western diet and body tissues than ALA (the n23
substrate of D6D), with an n26/n23 fatty acid ratio of .10:1
[13,14]. Therefore, high levels of endogenous AA are synthesized
and contribute to eicosanoid production. It has been suggested
that endogenous and exogenous AA are metabolized differently,
with more endogenous AA being metabolized into pro-inflamma-
tory eicosanoids [24]. Thus, increased D6D predominantly favors
the LA-AA pathway and greatly increases the amount of
Table 1. Fatty acid composition of B16 and LLC tumor tissues (% of total fatty acids).
C18:1 (OA)
C18:2n6
(LA)
C18:3n3
(ALA)
C20:3n6
(ETA)
C20:4n6
(AA)
C20:5n3
(EPA)
C22:4n6
(DTA)
C22:5n6
(DPAn6)
C22:5n6
(DPAn3)
C22:6n6
(DHA)
B16 Vehicle 24.5861.55 16.4164.31 0.1260.04 1.5460.16 4.6660.32 UD 0.6460.06 0.0360.04 0.1260.01 0.3760.04
SC-26196 27.362.24 18.5362.81 0.1360.02 1.0160.28
a 1.9460.31
b UD 0.2760.03
b UD UD 0.0460.07
b
Vector 24.0561.63 12.6361.48 0.1460.02 1.7160.24 6.1860.67 0.1860.04 0.6660.09 UD 0.1760.08 0.3160.14
RNAi 30.2863.21
a 19.7561.42
b 0.1160.05
b 0.8860.29
b 2.0160.64
b 0.1260.09 0.0660.1
b UD UD 0.0760.09
b
LLC Vehicle 11.8261.18 15.2561.23 0.960.35 0.6760.09 7.9860.78 0.0960.04 2.9460.54 0.7960.47 0.5560.09 2.1160.31
SC-26196 19.1861.42
b 25.5463.98
a 1.0260.76 0.4360.29 2.7661.17
b 0.0360.01
a 0.7960.32
b 0.1660.08 0.2860.13 0.5660.25
b
Vector 13.9561.95 16.5962.22 1.260.46 0.6860.13 8.9561.47 UD 4.5160.58 UD 0.2560.36 1.3560.39
RNAi 21.2863.81
b 21.3963.18
b 2.2960.77
a 0.4260.14
b 4.7361.17
b UD 2.4660.44
b UD UD 0.5560.18
b
The data are expressed as means 6 SD. UD: undetectable.
aP,0.05,
bP,0.01, compared to vehicle or vector control. Student’s t-test.
doi:10.1371/journal.pone.0047567.t001
Figure 3. Decreased D6D reduces the levels of AA and AA-derived eicosanoids in tumor tissue. Knocking down D6D (with RNAi) or
inhibiting D6D (with selective inhibitor SC-26196) decreased (a) AA and (b) AA metabolite levels in mouse models of B16 melanoma and LLC.
*P,0.05; **P,0.01; n=3–5.
doi:10.1371/journal.pone.0047567.g003
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eicosanoids.
Our findings that the expression and activity of the biomarkers
of D6D and the levels of AA are remarkably higher in tumor than
adjacent normal tissues, as well as our observation that tumor size
is positively correlated with higher activity of the biomarkers of
D6D activity, suggest that D6D plays a key role in tumorigenesis.
Our consistent results in the increased expression and functional
activity of D6D in two different cancer types (melanoma and lung
cancer) point to the possibility that up-regulation of D6D is a
common characteristic of malignant tumors. This possibility is
supported by previous studies in humans using microarray analysis
that have shown a significant difference in D6D mRNA between
tumor and normal tissues (.2-fold higher in tumors than in
normal tissue) from patients with breast cancer or brain tumors
[25,26]. Nevertheless, further study is warranted to examine the
D6D status of human tumor samples of various cancer types. We
noticed that there was a considerable amount of AA in adjacent
normal tissues in the context of almost undetectable D6D
expression. We assumed that this AA was synthesized in other
tissues or organs (e.g., the liver) and transferred through the
circulation system. The mechanisms by which D6D is up-
regulated during tumor development remain to be explored. We
speculate that D6D is up-regulated by increased activity of
SREBP-1c or PPARa in a tumor microenvironment characterized
by hypoxia and aberrant energy metabolism. Previous studies have
shown that D6D expression may be regulated by SREBP-1c [27]
and that SREBP-1c can be stimulated under hypoxic conditions
via hypoxia inducible factor-1alpha (HIF-1a) [28]. In addition,
SREBP-1c is the key factor for up-regulating fatty acid synthesis in
many cancers [29]. Given the fact that hypoxia and increased
ROS are common conditions in the tumor microenvironment, it is
possible that D6D expression in tumors results from the following
pathway: Hypoxia/ROS R HIF-1a R SREBP-1c R D6D. Thus,
the discovery of increased D6D activity in tumors opens up a new
field of investigation in cancer biology. Our findings suggest that
increased expression and activity of D6D is potentially a new
cancer biomarker.
Our results showing that inhibition of D6D activity, by either
RNAi-knockdown or a selective inhibitor, is highly effective in
suppressing tumor growth indicate that D6D is a target for cancer
therapy. Given that D6D is the rate-limiting enzyme for AA
synthesis and that LA is the major substrate for generating AA in
our bodies, it is conceivable that the activity of D6D is critical for
the production of AA and AA-derived pro-cancer eicosanoids and
thereby affects tumorigenesis. From knowledge of these biochem-
ical pathways, it is logical to speculate that D6D inhibition was
effective in this study due to its inhibition of AA and its
metabolites. D6D inhibition, which has a target upstream of AA
metabolism, is more efficient in reducing pro-cancer eicosanoid
production compared to the inhibition of individual pathways such
as COX, LOX, or P450 (by which pro-cancer AA metabolites
form), thus making D6D inhibition potentially more effective in
suppressing cancer development. Thus far, therapeutic agents that
target AA production/D6D activity do not exist, so the
development of such drugs may provide effective therapeutic
options, as demonstrated in the present study by the high efficacy
of SC-26196, a selective D6D inhibitor. This idea also supported
by a previous study showing that SC-26196 impeded intestinal
tumorigenesis by inhibiting the synthesis of AA [30].
During treatment with SC-26196, we did not observe any signs
of toxicity in the mice such as reduced mobility, piloerection,
hunched-back posture, etc. In addition, D6D-RNAi and SC-
26196 at concentrations of up to 128 mM did not show significant
growth suppression in both B16 and LLC cells in vitro (Figure S7),
suggesting that blocking D6D is not directly toxic to cancer cells.
However, cell proliferation is not necessarily related to tumor
growth and is probably not an accurate measure of the effects of
D6D inhibition on cancer. Rather, the anti-tumor effect of D6D
inhibition is likely due to its impact on the tumor microenviron-
ment, such as angiogenesis and inflammation, which are the key
factors that facilitate tumor growth and survival [4,5]. It is well
documented that AA-derived eicosanoids play a central role in
inflammation [5–7,31]. Inflammatory cells (e.g., macrophages,
neutrophils, natural killer cells, etc.) and factors (e.g., PGE2,
matrix metallopeptidases, interleukins, chemokines, etc.) are well-
known to induce angiogenesis [32–34]. A growing body of
Figure 4. Decreased D6D suppresses tumor angiogenesis and inflammation. (a) SC-26196, a D6D selective inhibitor, at 100 mM significantly
inhibited basic fibroblast growth factor (bFGF)-induced angiogenesis in a Matrigel plug assay (**P,0.01; n=3). (b, c) Immunohistological staining of
microvessel density in tumors. Knocking down D6D (with RNAi) or inhibiting D6D (with selective inhibitor SC-26196) reduced angiogenesis in (b) B16
melanoma and (c) LLC tumors (**P,0.01; n=3). (d) The mRNA expression of the inflammatory factors interleukin-6 (IL-6) and TNF-a is down-
regulated in B16 melanoma and LLC lung tumors treated with D6D-RNAi or SC-26196, shown here by percent of control. **P,0.01; n=4.
doi:10.1371/journal.pone.0047567.g004
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angiogenesis by up-regulating angiogenic factors. PGE2 stimulates
angiogenesis by activating the fibroblast growth factor receptor
(FGFR), epidermal growth factor receptor (EGFR) and b3 integrin
through E prostanoid 2 (EP2)- and EP4-mediated pathways
[5,35,36]. Lipoxygenase metabolites, including 12-HETE and 15-
HETE, have also been reported to promote angiogenesis by
inducing FGF [37], interleukin-8 (IL-8, a macrophage-derived
mediator of angiogenesis) [38], and vascular endothelial growth
factor (VEGF) [39]. Our results revealed that the pro-angiogenic,
AA-derived eicosanoids PGE2, 12-HETE, and 15-HETE, as well
as the key inflammatory factors interleukin-6 (IL-6) and tumor
necrosis factor a (TNF-a), were dramatically reduced in B16
melanoma and LLC tumors treated with D6D-RNAi or SC-26196
(Figures 3B, 4D). This suggests that blocking D6D can inhibit
inflammation and angiogenesis. Indeed, a remarkable reduction in
tumor angiogenesis, as evaluated by immunohistological staining
and an in vivo angiogenesis model, was observed in the tumors
treated with D6D-RNAi or SC-26196 (Figures 4A–C). Altogeth-
er, our results demonstrate that inhibition of D6D can diminish
the production of AA and AA-derived eicosanoids, leading to the
reduction of inflammation and angiogenesis and consequently, the
suppression of tumor growth.
A potential problem is that D6D inhibition may cause a
deficiency of long chain n26 and n23 fatty acids (i.e., AA and
EPA) in normal tissue. However, because the content of AA in the
modern Western diet and body tissues is very high (and even
excessive for most people), D6D inhibition would not deplete all
AA but simply reduce its endogenous production. In fact, our
animals treated with the D6D inhibitor showed no significant side
effects. Regarding the long chain n23 fatty acids (i.e., EPA, DHA),
these are mainly derived from specific foods (fish and fish oils), and
dietary supplementation of the n23 fatty acids can readily prevent
a deficiency. Given the capability of n23 fatty acids to compete
with n26 fatty acids for metabolism, thereby reducing AA-derived
eicosanoids and their anti-cancer properties, the supplementation
of n23 fatty acids together with the use of D6D inhibitors might
not only make D6D inhibition safer, but also enhance its anti-
cancer efficacy. As the exogenous AA from animal products may
still interfere with the outcome of D6D-inhibition therapy to some
extent, the consumption of AA-containing products must be
restricted during the treatment. Still, we acknowledge that AA and
its metabolites are naturally occurring and essential factors in
maintaining normal functioning of the immune system, heart,
brain, testes, etc. At present, it is unknown whether there are
detrimental effects of significantly reduced AA content due to D6D
inhibition, and how long-term use of a D6D inhibitor might
impact health. These are important issues that will need to be
carefully addressed in future studies.
Our discovery of D6D’s role in tumorigenesis also points to the
importance of tissue n26 and n23 fatty acid status in cancer
prevention. Because of the competition between n26 and n23
fatty acids for D6D and other metabolizing enzymes, the relative
amounts, or the ratio, of these two classes of fatty acids may be a
key factor for tumorigenesis. The severe imbalance between n26
and n23 fatty acids (n26/n23.10) in the modern Western diet
and human body tissue has been thought to contribute to today’s
increased risk of diseases, including cancer [14,18]. Evidence from
recent studies using the transgenic fat-1 mouse model, which can
endogenously convert n26t on 23 fatty acids and has a balanced
n26/n23 ratio in its body tissues [40], strongly supports this
notion [41–48]. These studies have demonstrated that decreasing
the tissue ratio of n26/n23 can significantly reduce the formation
and growth of various cancers, which is associated with reduced
levels of cancer-related eicosanoids and genes [41–48], suggesting
that the tumor-promoting effect of increased D6D activity can be
diminished by decreasing tissue n26/n23 fatty acid ratio. While
further study is warranted to explore this exciting field, the results
of the present study increase our understanding of the importance
of D6D as well as that of the tissue ratio of n26/n23 in cancer
prevention and also point to a potentially safe and effective
approach to cancer prevention through balancing dietary intake of
n26/n23.
In summary, the results presented here demonstrate an
important role for the D6D enzyme in tumorigenesis and reveal
a link between lipid metabolism and cancer biology. D6D may
serve as a new cancer biomarker and a potential target for the
development of novel anti-cancer drugs. The results also highlight
the potential utility of n23 fatty acid supplementation and
balancing the tissue ratio of n26/n23 fatty acids for cancer
prevention and treatment.
Supporting Information
Figure S1 Metabolism of polyunsaturated fatty acids.
The long-chain polyunsaturated fatty acids n26 arachidonic acid
(AA) and n23 eicosapentaenoic acid (EPA) are derived from LA
and ALA through a series of desaturation and chain-elongation
enzyme systems and are metabolized through the three major
pathways cyclooxygenase (COX), lipoxygenase (LOX), and
cytochrome P450 epoxygenase. Please note that delta-6 desaturase
(D6D) is the rate-limiting enzyme for the synthesis of both n26
AA and n23 EPA. Furthermore, the two classes of fatty acids
(n26 and n23) compete for the same enzymes for both synthesis
and metabolism.
(TIF)
Figure S2 The schematic structure of the pLu6-RNAi-
D6D plasmid.
(TIF)
Figure S3 Identification and quantification of AA-de-
rived eicosanoids were determined by LC- MS. A gradient
chromatographic separation was performed on a ZORBAX
Eclipse XDB-C18 column (Agilent, 5 mm, 7564.6 mm) at 25uC.
The detection was made in the negative mode. D4-PGE2 was used
as an internal standard for quantification of all eicosanoids. The
concentrations of eicosanoids in the samples were calculated by
comparing their ratios of peak areas of compounds to the internal
standards.
(TIF)
Figure S4 D6D mRNA expression in B16 and LLC cells
treated with D6D-RNAi in vitro.
(TIF)
Figure S5 D6D activity in B16 and LLC cells treated
with D6D-RNAi in vitro.
(TIF)
Figure S6 Gas chromatography showing the differences
in LA, ETA and AA content in treated (with D6D-RNAi or
SC-26196) or non-treated tumors.
(TIF)
Figure S7 Viability of B16 and LLC cells treated with
D6D-RNAi and SC-26196 in vitro. P.0.05; n=4.
(TIF)
Table S1 Dietary fatty acid composition for C57BL6 mice.
(TIF)
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